AbCellera's platform generates lumpy, milestone-dependent revenue, with quarterly revenue swinging from $44.9M in 2025Q4 to $4.0M in 2026Q2, while operating expenses remain elevated at ~$60M per quarter, leading to persistent net losses and negative free cash ...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | -$0.18-9.8% vs -$0.16 | $4M-48.4% vs $8M |
Q2 2026 May 11, 2026 | -$0.14+36.4% vs -$0.22 | $8M+53.6% vs $5M |
Q1 2026 Feb 24, 2026 | -$0.03+83.3% vs -$0.18 | $45M+572.9% vs $7M |
Q4 2025 Nov 6, 2025 | -$0.19-11.8% vs -$0.17 | $9M+41.9% vs $6M |
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026.
BlackRock Inc. purchased a new position in shares of AbCellera Biologics Inc. (NASDAQ: ABCL) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 3,805,309 shares of the company's stock, valued at approximately $29,872,000. BlackRock Inc. owned 1.25% of AbCellera
AbCellera Biologics Inc. (NASDAQ:ABCL) stock is trading higher on Tuesday. Year-to-date, the stock has jumped over 250%.
Benchmark ABCL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for AbCellera Biologics Inc. (ABCL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $12.65 | $3.86B | -25.82 | 160.56% | -194.88% | -14.47% | — | |
| $164.60 | $10.25B | -126.62 | 20.32% | -31.66% | -29.89% | — | |
| $4.05 | $2.12B | -2.81 | 26.92% | -945.92% | -50.41% | — | |
| $30.70 | $2.29B | -21.77 | 23.29% | -20.98% | -16.37% | — | |
| $25.93 | $2.67B | -32.01 | 120.01% | -54.75% | -7.7% | — | |
| $1.86 | $102.27M | -1.45 | 15.57% | -490.71% | -27.23% | — |
AbCellera Biologics Inc. (ABCL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
AbCellera Biologics Inc. (ABCL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Aug 10, 2026·SEC
Aug 7, 2026·SEC
Get notified when ABCL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AbCellera Biologics Inc. (ABCL) stock FAQ — growth, dividends, profitability & financials explained
AbCellera Biologics Inc. (ABCL) reported $66.2M in revenue for fiscal year 2025. This represents a 649% increase from $8.8M in 2018.
AbCellera Biologics Inc. (ABCL) grew revenue by 160.6% over the past year. This is strong growth.
AbCellera Biologics Inc. (ABCL) reported a net loss of $164.7M for fiscal year 2025.
AbCellera Biologics Inc. (ABCL) has a return on equity (ROE) of -14.5%. Negative ROE indicates the company is unprofitable.
AbCellera Biologics Inc. (ABCL) had negative free cash flow of $179.5M in fiscal year 2025, likely due to heavy capital investments.
